Abstract |
Recent studies have shown that the histone deacetylase-8 (HDAC8), as one of the HDACs, regulates the expression and activity of various genes involved in cancer initiation and progression. The HDAC8 plays an epigenetic role to dysregulate expressions or to interact with transcription factors. Most researchers had focused on the HDAC 1-3 and 6, but today the HDAC8 isotype is a promising target in cancer therapy. Different studies, on breast cancer (BC) cells, have recently shown the HDAC8 overexpression and suggested its oncogenic potential. It seems that the HDAC8 could be a novel and promising target in breast cancer treatment. Some studies on BC demonstrated therapeutic properties of the inhibitors of HDAC8 such as suberoylanilide hydroxamic acid (SAHA), Trichostatin A, valproic acid, sodium butyrate, 1,3,4 oxadiazole with alanine hybrid [(R)-2-amino-N-((5-phenyl-1,3,4-oxadiazol-2-yl) methyl) propanamide (10b)], N-(2-Hydroxyphenyl)-2propylpentanamide (compound 2) and PCI-34051. In this review, we highlight the role and existing inhibitors of HDAC8 in BC pathogenesis and therapy.
|
Authors | Golebagh Rahmani, Saba Sameri, Nooshin Abbasi, Mohammad Abdi, Rezvan Najafi |
Journal | Pathology, research and practice
(Pathol Res Pract)
Vol. 220
Pg. 153396
(Apr 2021)
ISSN: 1618-0631 [Electronic] Germany |
PMID | 33691240
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2021 Elsevier GmbH. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Biomarkers, Tumor
- Histone Deacetylase Inhibitors
- Repressor Proteins
- HDAC8 protein, human
- Histone Deacetylases
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Biomarkers, Tumor
(antagonists & inhibitors, metabolism)
- Breast Neoplasms
(drug therapy, enzymology, genetics, pathology)
- Epigenesis, Genetic
- Female
- Gene Expression Regulation, Neoplastic
- Histone Deacetylase Inhibitors
(therapeutic use)
- Histone Deacetylases
(metabolism)
- Humans
- Repressor Proteins
(antagonists & inhibitors, metabolism)
|